Compensatory mutations in agrC partly restore fitness in vitro to peptide deformylase inhibitor-resistant Staphylococcus aureus

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 8, 2012, Pages 1835-1842

  Zorzet, Anna ^a   Andersen, Jytte Mark ^b   Nilsson, Annika I ^a   Møller, Niels Frimodt ^b   Andersson, Dan I ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

Antibiotic resistance; Experimental evolution; Neutropenic mice; Protein synthesis

Indexed keywords

ACTINONIN; BACTERIAL DNA; BACTERIAL PROTEIN; BACTERIAL PROTEIN AGRC; PEPTIDE DEFORMYLASE INHIBITOR; UNCLASSIFIED DRUG;

ACTINONIN RESISTANT STAPHYLOCOCCUS AUREUS; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATION; BACTERIUM MUTANT; DNA SEQUENCE; FEMALE; GENE ISOLATION; GENE MUTATION; GROWTH RATE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYOSITIS; NEUTROPENIA; NONHUMAN; STAPHYLOCOCCUS AUREUS; THIGH; WILD TYPE;

AMIDOHYDROLASES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CULTURE MEDIA; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; FEMALE; MICE; MICROBIAL SENSITIVITY TESTS; PROTEIN KINASES; SERIAL PASSAGE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SUPPRESSION, GENETIC; VIRULENCE;

EID: 84864520020     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks168     Document Type: Article

References (32)

1. Marcker K, Sanger F. N-formyl-methionyl-S-RNA. J Mol Biol 1964; 8: 835-40.
2. Sundari RM, Stringer EA, Schulman LH et al. Interaction of bacterial initiation factor 2 with initiator tRNA. J Biol Chem 1976; 251: 3338-45.
3. Steiner-Mosonyi M, Creuzenet C, Keates RA et al. The Pseudomonas aeruginosa initiation factor IF-2 is responsible for formylationindependent protein initiation in P. aeruginosa. J Biol Chem 2004; 279: 52262-9.
4. Adams JM. On the release of the formyl group from nascent protein. J Mol Biol 1968; 33: 571-89.
5. Jain R, Chen D, White RJ et al. Bacterial peptide deformylase inhibitors: a new class of antibacterial agents. Curr Med Chem 2005; 12: 1607-21.
6. Fritsche TR, Sader HS, Cleeland R et al. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. Antimicrob Agents Chemother 2005; 49: 1468-76.
7. Lofland D, Difuntorum S, Waller A et al. In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698. J Antimicrob Chemother 2004; 53: 664-8.
8. Guay DR. Drug forecast-the peptide deformylase inhibitors as antibacterial agents. Ther Clin Risk Manag 2007; 3: 513-25.
9. Osborne CS, Neckermann G, Fischer E et al. In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. Antimicrob Agents Chemother 2009; 53: 3777-81.
10. Rolan P, Sun H, Macleod C et al. Pharmacokinetics and unexpected safety issues of LBM415, a novel oral peptide deformylase inhibitor. Clin Pharmacol Ther 2011; 90: 256-62.
11. Ross JE, Scangarella-Oman NE, Miller LA et al. Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor. J Clin Microbiol 2011; 49: 3928-30.
12. Clements JM, Beckett RP, Brown A et al. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother 2001; 45: 563-70.
13. Guillon JM, Mechulam Y, Schmitter JM et al. Disruption of the gene for Met-tRNA(fMet) formyltransferase severely impairs growth of Escherichia coli. J Bacteriol 1992; 174: 4294-301.
14. Margolis PS, Hackbarth CJ, Young DC et al. Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob Agents Chemother 2000; 44: 1825-31.
15. Duroc Y, Giglione C, Meinnel T. Mutations in three distinct loci cause resistance to peptide deformylase inhibitors in Bacillus subtilis. Antimicrob Agents Chemother 2009; 53: 1673-8.
16. Dean CR, Narayan S, Richards J et al. Reduced susceptibility of Haemophilus influenzae to the peptide deformylase inhibitor LBM415 can result from target protein overexpression due to amplified chromosomal def gene copy number. Antimicrob Agents Chemother 2007; 51: 1004-10.
17. Nilsson AI, Zorzet A, Kanth A et al. Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. Proc Natl Acad Sci USA 2006; 103: 6976-81.
18. Margolis P, Hackbarth C, Lopez S et al. Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB. Antimicrob Agents Chemother 2001; 45: 2432-5.
19. Proctor RA, von Eiff C, Kahl BC et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 2006; 4: 295-305.
20. Zorzet A, Pavlov MY, Nilsson AI et al. Error-prone initiation factor 2 mutations reduce the fitness cost of antibiotic resistance. Mol Microbiol 2010; 75: 1299-313.
21. Pavlov MY, Zorzet A, Andersson DI et al. Activation of initiation factor 2 by ligands and mutations for rapid docking of ribosomal subunits. EMBO J 2011; 30: 289-301.
22. Mangroo D, RajBhandary UL. Mutants of Escherichia coli initiator tRNA defective in initiation. Effects of overproduction of methionyl-tRNA transformylase and the initiation factors IF2 and IF3. J Biol Chem 1995; 270: 12203-9.
23. Vogelman B, Gudmundsson S, Turnidge J et al. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 1988; 157: 287-98.
24. Somerville GA, Beres SB, Fitzgerald JR et al. In vitro serial passage of Staphylococcus aureus: changes in physiology, virulence factor production, and agr nucleotide sequence. J Bacteriol 2002; 184: 1430-7.
25. Drusano GL, Liu W, Kulawy R et al. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother 2011; 55: 5300-5.
26. Jensen RO, Winzer K, Clarke SR et al. Differential recognition of Staphylococcus aureus quorum-sensing signals depends on both extracellular loops 1 and 2 of the transmembrane sensor AgrC. J Mol Biol 2008; 381: 300-9.
27. Ehrenberg M, Kurland CG. Costs of accuracy determined by a maximal growth rate constraint. Q Rev Biophys 1984; 17: 45-82.
28. Leeds JA, Dean CR. Peptide deformylase as an antibacterial target: a critical assessment. Curr Opin Pharmacol 2006; 6: 445-52.
29. Johnson KW, Lofland D, Moser HE. PDF inhibitors: an emerging class of antibacterial drugs. Curr Drug Targets Infect Disord 2005; 5: 39-52.
30. Sandegren L, Lindqvist A, Kahlmeter G et al. Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli. J Antimicrob Chemother 2008; 62: 495-503.
31. Andersson DI, Hughes D. Gene amplification and adaptive evolution in bacteria. Annu Rev Genet 2009; 43: 167-95.
32. Mader D, Rabiet MJ, Boulay F et al. Formyl peptide receptor-mediated proinflammatory consequences of peptide deformylase inhibition in Staphylococcus aureus. Microbes Infect 2010; 12: 415-9.